PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31

ProQR Therapeutics N.V.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026

$1.31+0.00 (0.00%)

Close on Oct 19, 2026

Debt

Borrowings on the balance sheet, Jun 30, 2026

ProQR Therapeutics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in ProQR Therapeutics's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in ProQR Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PRQR.

Revenue growth11.4% · median -87.5%

Operating margin-233.4% · median -940.6%

Net margin-228.9% · median -1052.2%

Company	Revenue	Growth
STOK	$27.59M	-86.2%
QURE	$18.67M	+30.2%
PRQR	€18.36M	+11.4%
KROS	$14.54M	-93.7%
NAMS	$7.12M	-88.9%
WVE	–	–

Company

Next earnings (est.): Nov 5, 2026, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 59
Auditor: KPMG Accountants N.V.
SEC CIK: 1612940

Advertisement
300 × 250